Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INSMED IncINSM · Entity 3174 | Director · Chair and CEO | July 23, 2026 | July 24, 2026 |
| NewAmsterdam Pharma Co N.V.NAMS · Entity 1826 | Director | January 07, 2026 | January 10, 2026 |
| uniQure N.V.QURE · Entity 4162 | Director | January 27, 2017 | January 31, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INSMED Inc
Report date July 23, 2026 · Filed July 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 259,058 |
Ending reported balance
After 2026-07-23 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-07-23 · Exercise / conversion · Acquired 6,260 · Balance 265,318 F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Row 2 · 2026-07-23 · Exercise / conversion · Acquired 4,440 · Balance 269,758 F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Row 3 · 2026-07-23 · Sale · Disposed 4,828 · Balance 264,930 F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2: This is the weighted average sales price representing 4,828 shares sold at prices ranging from $105.09 to $106.02 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Row 4 · 2026-07-23 · Sale · Disposed 5,872 · Balance 259,058 F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3: This is the weighted average sales price representing 5,872 shares sold at prices ranging from $106.09 to $106.78 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.46 · Expires 2028-01-04 | Direct | 0 |
Reported balance
After 2026-07-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-07-23 · Exercise / conversion · Disposed 6,260 · Balance 0 F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.16 · Expires 2027-05-17 | Direct | 0 |
Reported balance
After 2026-07-23 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-07-23 · Exercise / conversion · Disposed 4,440 · Balance 0 F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 233,924 |
Reported balance
Holding disclosure · report date 2026-07-23 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 233,924 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2: This is the weighted average sales price representing 4,828 shares sold at prices ranging from $105.09 to $106.02 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
F3: This is the weighted average sales price representing 5,872 shares sold at prices ranging from $106.09 to $106.78 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
F4: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.
NewAmsterdam Pharma Co N.V.
Report date January 07, 2026 · Filed January 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 10,360 |
Reported balance
After 2026-01-07 transaction · row 1
1 source rowRow 1 · 2026-01-07 · Grant · Acquired 3,400 · Balance 10,360 F1: Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date. F2: Each RSU was granted on January 7, 2026 for no consideration. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.45 · Expires 2036-01-07 | Direct | 15,300 |
Reported balance
After 2026-01-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-07 · Grant · Acquired 15,300 · Balance 15,300 F3: All of the ordinary shares underlying the option will vest on January 2, 2027, the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.
F2: Each RSU was granted on January 7, 2026 for no consideration.
F3: All of the ordinary shares underlying the option will vest on January 2, 2027, the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.
uniQure N.V.
Report date January 27, 2017 · Filed January 31, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.37 · Expires 2027-01-27 | Direct | 11,000 |
Reported balance
After 2017-01-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-27 · Grant · Acquired 11,000 · Balance 11,000 F1: The Stock Option vests 100% on January 27, 2018. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 16,000 |
Reported balance
After 2017-01-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-01-27 · Grant · Acquired 11,000 · Balance 16,000 F2: The Restricted Stock Unit vests 100% on January 27, 2018. F3: Expiration date is not applicable as the vested Restricted Stock Units shall be settled on the first business day following the date that such Restricted Stock Units vests. |
Filing footnotes · ownership attribution and instrument terms
F1: The Stock Option vests 100% on January 27, 2018.
F2: The Restricted Stock Unit vests 100% on January 27, 2018.
F3: Expiration date is not applicable as the vested Restricted Stock Units shall be settled on the first business day following the date that such Restricted Stock Units vests.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 08, 2024 Filed Jan 10, 2024 21:15 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 24,951 | $29.11 | $726,323.61 |
DisclosureSEC source: 0001628280-24-001036 · wk-form4_1704921303.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 373,538 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 24,951 shares sold at prices ranging from $28.71 to $29.68 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 08, 2024 Filed Jan 10, 2024 21:15 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 24,951 | $20.49 | $511,245.99 |
DisclosureSEC source: 0001628280-24-001036 · wk-form4_1704921303.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 398,489 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 05, 2024 Filed Jan 5, 2024 22:29 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 6,979 | $29.26 | $204,195.07 |
DisclosureSEC source: 0001628280-24-000693 · wk-form4_1704493778.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 373,538 F3 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of Restricted Stock Units and to cover related broker fees. F4 · price: This is the weighted average sales price representing 6,979 shares sold at prices ranging from $29.24 to $29.26 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 04, 2024 Filed Jan 5, 2024 22:29 UTC | INSMED Inc INSM · Entity 3174 | GrantStock Option (right to buy) · Derivative | 186,970 | $0.00 Strike: $29.13 | $0.00 |
DisclosureSEC source: 0001628280-24-000693 · wk-form4_1704493778.xml · derivative · entry 5 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,970 Underlying: Common Stock · 186,970 shares Expires 2034-01-04 F5 · derivative.exercise_date: Stock options granted under the Company's Amended and Restated 2019 Incentive Plan. The options become exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary date of the date of grant. Read SEC document |
| January 04, 2024 Filed Jan 5, 2024 22:29 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 37,869 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-000693 · wk-form4_1704493778.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 380,517 F1 · shares: Represents Restricted Stock Units, each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan. The Restricted Stock Units vest and become available as follows: twenty five (25%) percent on each anniversary of the date of grant through the fourth anniversary date of the date of the grant. F2 · price: Each Restricted Stock Unit was received as a grant on January 4, 2024, for no consideration. Read SEC document |
| January 04, 2024 Filed Jan 9, 2024 00:43 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | GrantOption (right to buy) · Derivative | 100,000 | $0.00 Strike: $12.01 | $0.00 |
DisclosureSEC source: 0000950170-24-003155 · ownership.xml · derivative · entry 1 Lewis William · CIK 0001402051 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Ordinary Shares · 100,000 shares Expires 2034-01-04 F1 · derivative.exercise_date: 25% of the shares underlying the option will vest on January 4, 2025, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document |
| October 27, 2023 Filed Oct 31, 2023 20:04 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 57,000 | $0.00 Strike: $14.24 | $0.00 |
DisclosureSEC source: 0001628280-23-035712 · wk-form4_1698782649.xml · derivative · entry 17 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By ARTICLE 4 TRUST UNDER KATIE PROCTER DYNASTY TRUST Disclosed balance after: 0 Underlying: Common Stock · 57,000 shares Expires 2023-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F9 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vested on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable and were scheduled to expire on October 31, 2023. Read SEC document |
| October 27, 2023 Filed Oct 31, 2023 20:04 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 500 | $0.00 Strike: $14.24 | $0.00 |
DisclosureSEC source: 0001628280-23-035712 · wk-form4_1698782649.xml · derivative · entry 16 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By ARTICLE 4 TRUST UNDER WILLIAM LEWIS FAMILY LEGACY TRUST U/A 11/1/2020 Disclosed balance after: 0 Underlying: Common Stock · 500 shares Expires 2023-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vested on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable and were scheduled to expire on October 31, 2023. Read SEC document |
| October 27, 2023 Filed Oct 31, 2023 20:04 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 55,000 | $0.00 Strike: $14.24 | $0.00 |
DisclosureSEC source: 0001628280-23-035712 · wk-form4_1698782649.xml · derivative · entry 15 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By ARTICLE 4 TRUST UNDER WILLIAM LEWIS FAMILY LEGACY TRUST U/A 11/1/2020 Disclosed balance after: 500 Underlying: Common Stock · 55,000 shares Expires 2023-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F9 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vested on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable and were scheduled to expire on October 31, 2023. Read SEC document |
| October 27, 2023 Filed Oct 31, 2023 20:04 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 327 | $26.00 | $8,502.00 |
DisclosureSEC source: 0001628280-23-035712 · wk-form4_1698782649.xml · nonDerivative · entry 13 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · Indirect Disclosed balance after: 233,924 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · ownership.nature: By ARTICLE 4 KATIE PROCTER DYNASTY TRUST Read SEC document |
| October 27, 2023 Filed Oct 31, 2023 20:04 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 327 | $14.24 | $4,656.48 |
DisclosureSEC source: 0001628280-23-035712 · wk-form4_1698782649.xml · nonDerivative · entry 12 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · Indirect Disclosed balance after: 234,251 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · ownership.nature: By ARTICLE 4 KATIE PROCTER DYNASTY TRUST Read SEC document |
| October 27, 2023 Filed Oct 31, 2023 20:04 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 1,323 | $25.05 | $33,141.15 |
DisclosureSEC source: 0001628280-23-035712 · wk-form4_1698782649.xml · nonDerivative · entry 11 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · Indirect Disclosed balance after: 233,924 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F7 · price: This is the weighted average sales price representing 1,323 shares sold at prices ranging from $24.83 to $25.40 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. F5 · ownership.nature: By ARTICLE 4 KATIE PROCTER DYNASTY TRUST Read SEC document |
| October 27, 2023 Filed Oct 31, 2023 20:04 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 1,323 | $14.24 | $18,839.52 |
DisclosureSEC source: 0001628280-23-035712 · wk-form4_1698782649.xml · nonDerivative · entry 10 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · Indirect Disclosed balance after: 235,247 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · ownership.nature: By ARTICLE 4 KATIE PROCTER DYNASTY TRUST Read SEC document |
| October 27, 2023 Filed Oct 31, 2023 20:04 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 55,350 | $24.04 | $1,330,614.00 |
DisclosureSEC source: 0001628280-23-035712 · wk-form4_1698782649.xml · nonDerivative · entry 9 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · Indirect Disclosed balance after: 233,924 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6 · price: This is the weighted average sales price representing 55,350 shares sold at prices ranging from $23.65 to $24.63 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. F5 · ownership.nature: By ARTICLE 4 KATIE PROCTER DYNASTY TRUST Read SEC document |
| October 27, 2023 Filed Oct 31, 2023 20:04 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 55,350 | $14.24 | $788,184.00 |
DisclosureSEC source: 0001628280-23-035712 · wk-form4_1698782649.xml · nonDerivative · entry 8 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · Indirect Disclosed balance after: 289,274 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · ownership.nature: By ARTICLE 4 KATIE PROCTER DYNASTY TRUST Read SEC document |
| October 27, 2023 Filed Oct 31, 2023 20:04 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 500 | $14.24 | $7,120.00 |
DisclosureSEC source: 0001628280-23-035712 · wk-form4_1698782649.xml · nonDerivative · entry 7 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · Indirect Disclosed balance after: 500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · ownership.nature: By ARTICLE 4 TRUST UNDER WILLIAM LEWIS FAMILY LEGACY TRUST U/A11/1/2020 Read SEC document |
| October 27, 2023 Filed Oct 31, 2023 20:04 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 315 | $26.00 | $8,190.00 |
DisclosureSEC source: 0001628280-23-035712 · wk-form4_1698782649.xml · nonDerivative · entry 6 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · Indirect Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · ownership.nature: By ARTICLE 4 TRUST UNDER WILLIAM LEWIS FAMILY LEGACY TRUST U/A11/1/2020 Read SEC document |
| October 27, 2023 Filed Oct 31, 2023 20:04 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 315 | $14.24 | $4,485.60 |
DisclosureSEC source: 0001628280-23-035712 · wk-form4_1698782649.xml · nonDerivative · entry 5 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · Indirect Disclosed balance after: 315 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · ownership.nature: By ARTICLE 4 TRUST UNDER WILLIAM LEWIS FAMILY LEGACY TRUST U/A11/1/2020 Read SEC document |
| October 27, 2023 Filed Oct 31, 2023 20:04 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 1,322 | $25.08 | $33,155.76 |
DisclosureSEC source: 0001628280-23-035712 · wk-form4_1698782649.xml · nonDerivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · Indirect Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This is the weighted average sales price representing 1,322 shares sold at prices ranging from $24.83 to $25.40 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. F2 · ownership.nature: By ARTICLE 4 TRUST UNDER WILLIAM LEWIS FAMILY LEGACY TRUST U/A11/1/2020 Read SEC document |
| October 27, 2023 Filed Oct 31, 2023 20:04 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 1,322 | $14.24 | $18,825.28 |
DisclosureSEC source: 0001628280-23-035712 · wk-form4_1698782649.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · Indirect Disclosed balance after: 1,322 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · ownership.nature: By ARTICLE 4 TRUST UNDER WILLIAM LEWIS FAMILY LEGACY TRUST U/A11/1/2020 Read SEC document |
| October 27, 2023 Filed Oct 31, 2023 20:04 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 53,363 | $24.04 | $1,282,846.52 |
DisclosureSEC source: 0001628280-23-035712 · wk-form4_1698782649.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · Indirect Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 53,363 shares sold at prices ranging from $23.68 to $24.60 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. F2 · ownership.nature: By ARTICLE 4 TRUST UNDER WILLIAM LEWIS FAMILY LEGACY TRUST U/A11/1/2020 Read SEC document |
| October 27, 2023 Filed Oct 31, 2023 20:04 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 53,363 | $14.24 | $759,889.12 |
DisclosureSEC source: 0001628280-23-035712 · wk-form4_1698782649.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · Indirect Disclosed balance after: 53,363 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · ownership.nature: By ARTICLE 4 TRUST UNDER WILLIAM LEWIS FAMILY LEGACY TRUST U/A11/1/2020 Read SEC document |
| May 17, 2023 Filed May 17, 2023 20:11 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 7,099 | $18.12 | $128,633.88 |
DisclosureSEC source: 0001628280-23-018684 · wf-form4_168435429831173.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 341,345 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of Restricted Stock Units and to cover related broker fees. F3 · price: This is a weighted average sales price representing 7,099 shares sold at prices ranging from $18.12 to $18.13 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| May 16, 2023 Filed May 17, 2023 20:11 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 3,714 | $18.41 | $68,374.74 |
DisclosureSEC source: 0001628280-23-018684 · wf-form4_168435429831173.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 348,444 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of Restricted Stock Units and to cover related broker fees. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:11 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 6,048 | $19.23 | $116,303.04 |
DisclosureSEC source: 0001628280-23-018684 · wf-form4_168435429831173.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 352,158 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of Restricted Stock Units and to cover related broker fees. F2 · price: This is a weighted average sales price representing 6,048 shares sold at prices ranging from $19.21 to $19.24 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| May 12, 2023 Filed May 15, 2023 20:12 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option · Derivative | 83,333 | $12.44 Strike: $12.44 | $1,036,662.52 |
DisclosureSEC source: 0001628280-23-018171 · wf-form4_168418150462788.xml · derivative · entry 8 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By ARTICLE 4 KATIE PROCTER DYNASTY TRUST Disclosed balance after: 0 Underlying: Common Stock · 83,333 shares Expires 2023-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vested on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| May 12, 2023 Filed May 15, 2023 20:12 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 83,334 | $12.44 Strike: $12.44 | $1,036,674.96 |
DisclosureSEC source: 0001628280-23-018171 · wf-form4_168418150462788.xml · derivative · entry 7 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By ARTICLE 4 TRUST UNDER KATIE PROCTER DYNASTY TRUST Disclosed balance after: 0 Underlying: Common Stock · 83,334 shares Expires 2023-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vested on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| May 12, 2023 Filed May 15, 2023 20:12 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 67,257 | $12.44 Strike: $12.44 | $836,677.08 |
DisclosureSEC source: 0001628280-23-018171 · wf-form4_168418150462788.xml · derivative · entry 6 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By ARTICLE 4 TRUST UNDER KATIE PROCTER DYNASTY TRUST Disclosed balance after: 0 Underlying: Common Stock · 67,257 shares Expires 2023-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vested on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| May 12, 2023 Filed May 15, 2023 20:12 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 83,334 | $12.44 | $1,036,674.96 |
DisclosureSEC source: 0001628280-23-018171 · wf-form4_168418150462788.xml · nonDerivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · Indirect Disclosed balance after: 233,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · ownership.nature: By ARTICLE 4 TRUST UNDER KATIE PROCTER DYNASTY TRUST, of which the reporting person is a trustee. The reporting person and members of the reporting person's immediate family are the sole beneficiaries of the trust. Read SEC document |
| May 12, 2023 Filed May 15, 2023 20:12 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 83,333 | $12.44 | $1,036,662.52 |
DisclosureSEC source: 0001628280-23-018171 · wf-form4_168418150462788.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · Indirect Disclosed balance after: 150,590 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · ownership.nature: By ARTICLE 4 TRUST UNDER KATIE PROCTER DYNASTY TRUST, of which the reporting person is a trustee. The reporting person and members of the reporting person's immediate family are the sole beneficiaries of the trust. Read SEC document |
| May 12, 2023 Filed May 15, 2023 20:12 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 67,257 | $12.44 | $836,677.08 |
DisclosureSEC source: 0001628280-23-018171 · wf-form4_168418150462788.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · Indirect Disclosed balance after: 67,257 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · ownership.nature: By ARTICLE 4 TRUST UNDER KATIE PROCTER DYNASTY TRUST, of which the reporting person is a trustee. The reporting person and members of the reporting person's immediate family are the sole beneficiaries of the trust. Read SEC document |
| May 11, 2023 Filed May 15, 2023 20:12 UTC | INSMED Inc INSM · Entity 3174 | GrantStock Option (right to buy) · Derivative | 430,140 | $0.00 Strike: $18.95 | $0.00 |
DisclosureSEC source: 0001628280-23-018171 · wf-form4_168418150462788.xml · derivative · entry 5 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 430,140 Underlying: Common Stock · 430,140 shares Expires 2033-05-11 F4 · derivative.exercise_date: Stock options granted under the Company's 2019 Incentive Plan. The options become exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary date of the date of grant. Read SEC document |
| May 11, 2023 Filed May 15, 2023 20:12 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 93,139 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-018171 · wf-form4_168418150462788.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 358,206 F1 · shares: Represents Restricted Stock Units, each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's 2019 Incentive Plan. The Restricted Stock Units vest and become available as follows: twenty five (25%) percent on each anniversary of the date of grant through the fourth anniversary date of the date of grant. F2 · price: Each Restricted Stock Unit was received as a grant on May 11, 2023, for no consideration. Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 21:10 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 6,994 | $18.00 | $125,892.00 |
DisclosureSEC source: 0001628280-23-000960 · wf-form4_167355782601813.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,067 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of Restricted Stock Units and to cover related broker fees. F2 · price: This is a weighted average sales price representing 6,994 shares sold at prices ranging from $17.97 to $18.02 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 21:24 UTC | INSMED Inc INSM · Entity 3174 | GrantStock Option (right to buy) · Derivative | 102,540 | $0.00 Strike: $19.74 | $0.00 |
DisclosureSEC source: 0001402051-23-000001 · wf-form4_167304024350073.xml · derivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,540 Underlying: Common Stock · 102,540 shares Expires 2033-01-05 F5 · derivative.exercise_date: Stock options granted under the Company's 2019 Incentive Plan. The options become exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary date of the date of grant. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 21:24 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 22,353 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001402051-23-000001 · wf-form4_167304024350073.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,061 F3 · shares: Represents Restricted Stock Units, each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's 2019 Incentive Plan. The Restricted Stock Units vest and become available as follows: twenty five (25%) percent on each anniversary of the date of grant through the fourth anniversary date of the date of grant. F4 · price: Each Restricted Stock Unit was received as a grant on January 5, 2023, for no consideration. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 21:24 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 7,008 | $19.80 | $138,758.40 |
DisclosureSEC source: 0001402051-23-000001 · wf-form4_167304024350073.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,708 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of Restricted Stock Units and to cover related broker fees. F2 · price: This is a weighted average sales price representing 7,008 shares sold at prices ranging from $19.78 to $19.805 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 20:18 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 186,170 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001402051-22-000003 · wf-form4_166016268759482.xml · derivative · entry 11 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By ARTICLE 4 TRUST UNDER WILLIAM LEWIS FAMILY LEGACY TRUST U/A 11/1/2020 Disclosed balance after: 0 Underlying: Common Stock · 186,170 shares Expires 2022-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vested on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 20:18 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 30,630 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001402051-22-000003 · wf-form4_166016268759482.xml · derivative · entry 10 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By ARTICLE 4 TRUST UNDER WILLIAM LEWIS FAMILY LEGACY TRUST U/A 11/1/2020 Disclosed balance after: 0 Underlying: Common Stock · 30,630 shares Expires 2022-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vested on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 20:18 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 24,977 | $28.43 | $710,096.11 |
DisclosureSEC source: 0001402051-22-000003 · wf-form4_166016268759482.xml · nonDerivative · entry 8 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Indirect Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6 · price: This is the weighted average sales price representing 24,977 shares sold at prices ranging from $28.26 to $28.72 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. F2 · ownership.nature: By ARTICLE 4 TRUST UNDER WILLIAM LEWIS FAMILY LEGACY TRUST U/A 11/1/2020 Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 20:18 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 24,977 | $4.55 | $113,645.35 |
DisclosureSEC source: 0001402051-22-000003 · wf-form4_166016268759482.xml · nonDerivative · entry 7 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Indirect Disclosed balance after: 24,977 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · ownership.nature: By ARTICLE 4 TRUST UNDER WILLIAM LEWIS FAMILY LEGACY TRUST U/A 11/1/2020 Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 20:18 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 161,193 | $27.75 | $4,473,105.75 |
DisclosureSEC source: 0001402051-22-000003 · wf-form4_166016268759482.xml · nonDerivative · entry 6 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Indirect Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · price: This is the weighted average sales price representing 161,193 shares sold at prices ranging from $27.26 to $28.25 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. F2 · ownership.nature: By ARTICLE 4 TRUST UNDER WILLIAM LEWIS FAMILY LEGACY TRUST U/A 11/1/2020 Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 20:18 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 161,193 | $4.55 | $733,428.15 |
DisclosureSEC source: 0001402051-22-000003 · wf-form4_166016268759482.xml · nonDerivative · entry 5 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Indirect Disclosed balance after: 161,193 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · ownership.nature: By ARTICLE 4 TRUST UNDER WILLIAM LEWIS FAMILY LEGACY TRUST U/A 11/1/2020 Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 20:18 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 6,200 | $28.45 | $176,390.00 |
DisclosureSEC source: 0001402051-22-000003 · wf-form4_166016268759482.xml · nonDerivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Indirect Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This is the weighted average sales price representing 6,200 shares sold at prices ranging from $28.26 to $28.73 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. F2 · ownership.nature: By ARTICLE 4 TRUST UNDER WILLIAM LEWIS FAMILY LEGACY TRUST U/A 11/1/2020 Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 20:18 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 6,200 | $3.40 | $21,080.00 |
DisclosureSEC source: 0001402051-22-000003 · wf-form4_166016268759482.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Indirect Disclosed balance after: 6,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · ownership.nature: By ARTICLE 4 TRUST UNDER WILLIAM LEWIS FAMILY LEGACY TRUST U/A 11/1/2020 Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 20:18 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 24,430 | $27.67 | $675,978.10 |
DisclosureSEC source: 0001402051-22-000003 · wf-form4_166016268759482.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Indirect Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 24,430 shares sold at prices ranging from $27.26 to $28.25 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. F2 · ownership.nature: By ARTICLE 4 TRUST UNDER WILLIAM LEWIS FAMILY LEGACY TRUST U/A 11/1/2020 Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 20:18 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 24,430 | $3.40 | $83,062.00 |
DisclosureSEC source: 0001402051-22-000003 · wf-form4_166016268759482.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Indirect Disclosed balance after: 24,430 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · ownership.nature: By ARTICLE 4 TRUST UNDER WILLIAM LEWIS FAMILY LEGACY TRUST U/A 11/1/2020 Read SEC document |
| July 07, 2022 Filed Jul 8, 2022 20:04 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 96,614 | $0.00 Strike: $16.16 | $0.00 |
DisclosureSEC source: 0001402051-22-000002 · wf-form4_165731066077799.xml · derivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 96,614 shares Expires 2026-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vested on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| July 07, 2022 Filed Jul 8, 2022 20:04 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 96,614 | $23.00 | $2,222,122.00 |
DisclosureSEC source: 0001402051-22-000002 · wf-form4_165731066077799.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,716 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 96,614 shares sold at prices ranging from $23.00 to $23.03 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| July 07, 2022 Filed Jul 8, 2022 20:04 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 96,614 | $16.16 | $1,561,282.24 |
DisclosureSEC source: 0001402051-22-000002 · wf-form4_165731066077799.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,330 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes 888 shares acquired through the Company's 2018 Employee Stock Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.